Author’s response to reviews

Title: FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer

Authors:

Susan J Dutton (susan.dutton@csm.ox.ac.uk)
Nicola Kenealy (foxfire@octo-oxford.org.uk)
Sharon Love (sharon.love@ndorms.ox.ac.uk)
Harpreet S Wasan (hwasan1@aol.com)
Ricky A Sharma (ricky.sharma@oncology.ox.ac.uk)

Version: 2
Date: 14 April 2014

Author’s response to reviews:

1. Ethical and Funding Approval Documentation

As requested, I have forwarded copies of all ethical approval and funding approval to BMCSeriesEditorial@biomedcentral.com.

2. Funding

This study is externally funded since the investigators were awarded a grant by Cancer Research UK for the study following peer-review. This study has also received assistance from Sirtex Medical Ltd, and this has been clearly stated in the 'competing interests' section of the manuscript. The letter confirming funding of the study protocol following peer-review by Cancer Research UK has been sent to BMCSeriesEditorial@biomedcentral.com by email.

3. Study status

This study is ongoing. It will continue to recruit patients until October 2014, follow-up patients until 2016 and analyze data until 2017.

4. Related Articles

None of the results of this study have been published in any journal.